biostudies-literatureChen JNational Major Scientific Research Project of ChinaClinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center of ChinaInternational Scientific and Technological Cooperation Project of ChinaShanghai Science and Technology Commission Research Project of China21https://www.ebi.ac.uk/biostudies/studies/S-EPMC9909954biostudies-literatureUnknown23(1)<h4>Background</h4>Apatinib (YN968D1) is the first small-molecule-targeting drug with anti-tumor activity created in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It showed significant variation in the efficacy for treating cancers, including advanced non-squamous non-small-cell lung cancer (NSCLC). Whether its efficacy could be optimized by subgrouping patients with certain genetic variation remains elusive.<h4>Methods</h4>Here, we firstly used kinase screening to identify any possible target of apatinib against 138 kinases. The effects of apatinib on proliferation rates, cell cycle, cell apoptosis, and cell migration on cancer cell lines were analyzed; the in vitro potential pathways of apatinib on cancer cell lines were screened. The effect Cancer cell internationalIn vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.PMC990995413DZ19306022015CB931803SHDC120151202015DFA31810Chen JChen WWei HZhai JLiu SLi MGong XYu HfalseIn vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.<h4>Background</h4>Apatinib (YN968D1) is the first small-molecule-targeting drug with anti-tumor activity created in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It showed significant variation in the efficacy for treating cancers, including advanced non-squamous non-small-cell lung cancer (NSCLC). Whether its efficacy could be optimized by subgrouping patients with certain genetic variation remains elusive.<h4>Methods</h4>Here, we firstly used kinase screening to identify any possible target of apatinib against 138 kinases. The effects of apatinib on proliferation rates, cell cycle, cell apoptosis, and cell migration on cancer cell lines were analyzed; the in vitro potential pathways of apatinib on cancer cell lines were screened. The effect 2023-01-01T00:00:00Z2023 Feb2025-04-26T22:33:31.936Z2024-11-21T01:57:30.455ZS-EPMC99099543675981810.1186/s12935-022-02723-7